Sir­naomics puts off an IPO a lit­tle longer as it pock­ets an­oth­er megaround. Is an S-1 around the cor­ner this time?

Back in Oc­to­ber, when small in­ter­fer­ing RNA play­er Sir­naomics land­ed its Se­ries D round, CEO Patrick Lu said he was open to prepar­ing for an IPO “in (the) near fu­ture.” Those S-1 pa­pers nev­er came, and now Lu’s tak­ing an­oth­er trip down VC lane.

Sir­naomics un­veiled a $105 mil­lion Se­ries E round on Thurs­day, led by the same firm that led the last megaround: Ro­tat­ing Boul­der Fund. The biotech says it will pump the funds in­to its RNAi port­fo­lio aimed at treat­ing can­cers, vi­ral in­fec­tions, fi­bro­sis and meta­bol­ic dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER